Article info

Download PDFPDF

Original article
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

Authors

  1. Correspondence to Dr Xenofon Baraliakos; Xenofon.Baraliakos{at}elisabethgruppe.de
View Full Text

Citation

Baraliakos X, Braun J, Deodhar A on behalf of the MEASURE 1 study group, et al
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

Publication history

  • Received May 9, 2019
  • Revision received July 26, 2019
  • Accepted August 18, 2019
  • First published September 3, 2019.
Online issue publication 
September 03, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.